Author
Listed:
- Stefan Gröschel
(German Cancer Research Center (DKFZ)
Heidelberg University Hospital
German Cancer Consortium (DKTK))
- Daniel Hübschmann
(DKFZ
DKFZ
Heidelberg Institute for Stem Cell Technology and Experimental Medicine
Heidelberg University Hospital)
- Francesco Raimondi
(Heidelberg University
Heidelberg University Biochemistry Center)
- Peter Horak
(German Cancer Consortium (DKTK)
National Center for Tumor Diseases (NCT) Heidelberg and DKFZ)
- Gregor Warsow
(DKFZ
DKFZ)
- Martina Fröhlich
(German Cancer Consortium (DKTK)
DKFZ and NCT Heidelberg)
- Barbara Klink
(Technische Universität Dresden
DKTK)
- Laura Gieldon
(Technische Universität Dresden
DKTK)
- Barbara Hutter
(German Cancer Consortium (DKTK)
DKFZ and NCT Heidelberg)
- Kortine Kleinheinz
(DKFZ
Heidelberg University)
- David Bonekamp
(DKFZ)
- Oliver Marschal
(Onkologische Schwerpunktpraxis)
- Priya Chudasama
(German Cancer Consortium (DKTK)
National Center for Tumor Diseases (NCT) Heidelberg and DKFZ)
- Jagoda Mika
(German Cancer Research Center (DKFZ)
Heidelberg University)
- Marie Groth
(National Center for Tumor Diseases (NCT) Heidelberg and DKFZ
Heidelberg University)
- Sebastian Uhrig
(German Cancer Consortium (DKTK)
DKFZ and NCT Heidelberg
Heidelberg University)
- Stephen Krämer
(DKFZ
Heidelberg University)
- Christoph Heining
(DKTK
NCT Dresden and University Hospital Carl Gustav Carus)
- Christoph E. Heilig
(National Center for Tumor Diseases (NCT) Heidelberg and DKFZ)
- Daniela Richter
(DKTK
NCT Dresden and University Hospital Carl Gustav Carus)
- Eva Reisinger
(DKFZ
DKFZ)
- Katrin Pfütze
(German Cancer Consortium (DKTK)
DKFZ-Heidelberg Center for Personalized Oncology (HIPO))
- Roland Eils
(German Cancer Consortium (DKTK)
DKFZ
DKFZ-Heidelberg Center for Personalized Oncology (HIPO))
- Stephan Wolf
(German Cancer Consortium (DKTK)
DKFZ)
- Christof Kalle
(German Cancer Consortium (DKTK)
DKFZ-Heidelberg Center for Personalized Oncology (HIPO)
National Center for Tumor Diseases (NCT) Heidelberg and DKFZ)
- Christian Brandts
(Goethe University
DKTK)
- Claudia Scholl
(German Cancer Consortium (DKTK)
DKFZ)
- Wilko Weichert
(Technical University Munich
DKTK)
- Stephan Richter
(DKTK
University Hospital Carl Gustav Carus)
- Sebastian Bauer
(University of Duisburg-Essen
DKTK)
- Roland Penzel
(German Cancer Consortium (DKTK)
Heidelberg University Hospital)
- Evelin Schröck
(Technische Universität Dresden
DKTK)
- Albrecht Stenzinger
(German Cancer Consortium (DKTK)
Heidelberg University Hospital)
- Richard F. Schlenk
(Heidelberg University Hospital
German Cancer Consortium (DKTK)
Heidelberg University Hospital
NCT Heidelberg and DKFZ)
- Benedikt Brors
(German Cancer Consortium (DKTK)
DKFZ and NCT Heidelberg)
- Robert B. Russell
(Heidelberg University
Heidelberg University Biochemistry Center)
- Hanno Glimm
(DKTK
NCT Dresden and University Hospital Carl Gustav Carus)
- Matthias Schlesner
(German Cancer Consortium (DKTK)
DKFZ
DKFZ)
- Stefan Fröhling
(German Cancer Consortium (DKTK)
National Center for Tumor Diseases (NCT) Heidelberg and DKFZ
DKFZ-Heidelberg Center for Personalized Oncology (HIPO))
Abstract
Chordomas are rare bone tumors with few therapeutic options. Here we show, using whole-exome and genome sequencing within a precision oncology program, that advanced chordomas (n = 11) may be characterized by genomic patterns indicative of defective homologous recombination (HR) DNA repair and alterations affecting HR-related genes, including, for example, deletions and pathogenic germline variants of BRCA2, NBN, and CHEK2. A mutational signature associated with HR deficiency was significantly enriched in 72.7% of samples and co-occurred with genomic instability. The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib, which is preferentially toxic to HR-incompetent cells, led to prolonged clinical benefit in a patient with refractory chordoma, and whole-genome analysis at progression revealed a PARP1 p.T910A mutation predicted to disrupt the autoinhibitory PARP1 helical domain. These findings uncover a therapeutic opportunity in chordoma that warrants further exploration, and provide insight into the mechanisms underlying PARP inhibitor resistance.
Suggested Citation
Stefan Gröschel & Daniel Hübschmann & Francesco Raimondi & Peter Horak & Gregor Warsow & Martina Fröhlich & Barbara Klink & Laura Gieldon & Barbara Hutter & Kortine Kleinheinz & David Bonekamp & Olive, 2019.
"Defective homologous recombination DNA repair as therapeutic target in advanced chordoma,"
Nature Communications, Nature, vol. 10(1), pages 1-9, December.
Handle:
RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-09633-9
DOI: 10.1038/s41467-019-09633-9
Download full text from publisher
Citations
Citations are extracted by the
CitEc Project, subscribe to its
RSS feed for this item.
Cited by:
- Mrinal M. Gounder & Narasimhan P. Agaram & Sally E. Trabucco & Victoria Robinson & Richard A. Ferraro & Sherri Z. Millis & Anita Krishnan & Jessica Lee & Steven Attia & Wassim Abida & Alexander Drilon, 2022.
"Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma,"
Nature Communications, Nature, vol. 13(1), pages 1-15, December.
- Tanaz Sharifnia & Mathias J. Wawer & Amy Goodale & Yenarae Lee & Mariya Kazachkova & Joshua M. Dempster & Sandrine Muller & Joan Levy & Daniel M. Freed & Josh Sommer & Jérémie Kalfon & Francisca Vazqu, 2023.
"Mapping the landscape of genetic dependencies in chordoma,"
Nature Communications, Nature, vol. 14(1), pages 1-17, December.
- Qilin Zhang & Ziyan Xu & Rui Han & Yunzhi Wang & Zhen Ye & Jiajun Zhu & Yixin Cai & Fan Zhang & Jiangyan Zhao & Boyuan Yao & Zhaoyu Qin & Nidan Qiao & Ruofan Huang & Jinwen Feng & Yongfei Wang & Wenti, 2024.
"Proteogenomic characterization of skull-base chordoma,"
Nature Communications, Nature, vol. 15(1), pages 1-32, December.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-09633-9. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.